Home > Insider Trading > Filing (0001209191-24-004124)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
822370	Emmaus Life Sciences Inc.	EMMA	Pharmaceutical Preparations (2834)	870419387

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1517775	C Willis Lee	21250 Hawthorne Blvd. Suite 800 Torrance CA 90503	Co-President & Coo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	Acquisiton	2024-02-26	13,200	$0.12	57,400	No	4	P	Indirect	By Fidelity Roth IRA FBO Willis C. Lee
Common Stock, $0.001 Par Value	Acquisiton	2024-02-27	10,000	$0.13	67,400	No	4	P	Indirect	By Fidelity Roth IRA FBO Willis C. Lee
Common Stock, $0.001 Par Value	Acquisiton	2024-02-28	15,000	$0.12	82,400	No	4	P	Indirect	By Fidelity Roth IRA FBO Willis C. Lee
Common Stock, $0.001 Par Value	Acquisiton	2024-02-29	77,000	$0.13	159,400	No	4	P	Indirect	By Fidelity Roth IRA FBO Willis C. Lee

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Fidelity Roth IRA FBO Willis C. Lee
No	4	P	Indirect	By Fidelity Roth IRA FBO Willis C. Lee
No	4	P	Indirect	By Fidelity Roth IRA FBO Willis C. Lee
No	4	P	Indirect	By Fidelity Roth IRA FBO Willis C. Lee

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	395,124	Direct
Common Stock, $0.001 Par Value	241,194	Indirect	By Fidelity Traditional IRA FBO Willis C. Lee

Footnotes

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive.